Speciality chemical stocks have faced significant challenges over the past few years, with many delivering negative returns.
There’s no single reason Indian speciality chemical stocks have not delivered strong returns, but a mix of sector-specific, macroeconomic and market dynamics explains the underperformance seen in many names.
In certain instances, global demand has been subdued, and in others, reduced end-market consumption has resulted in destocking, weaker offtake, and challenges for producers in terms of sales and margins.
Here we examine three best speciality chemical stocks that have failed to deliver any returns over the past three years, despite capital expenditure investments.
Aarti Industries
Aarti Industries specializes in speciality chemicals and intermediates used in a wide range of industries, including agrochemicals, pharmaceuticals, polymers and additives, pigments, dyes and surfactants, etc.
The stock of Aarti Industries has gone nowhere in the last three years. In fact, it has given negative returns of 13.76%.
The company has been impacted by “destocking”. Apart from this, China’s slowing domestic economy led its chemical giants to “dump” excess products into the global market at extremely low prices.
This forced Indian companies to lower their own prices to stay competitive, severely squeezing their operating margins.
Moving ahead, things seem to be getting better for Aarti Industries. According to the management, as China prioritizes higher-quality growth and enforces stricter supply-side discipline, the company anticipates a more rational global pricing environment.
For integrated, quality-focused players like Aarti, this transition could serve as a structural catalyst for sustainable margin recovery.
On the other hand, while the company has been navigating US tariff headwinds, the recently announced US-India Trade deal provides a sigh of relief and is expected to boost business there.
Overall, things seem to be getting much better for Aarti Industries. In Q3 FY26, the company's revenue stood at ₹2,492 crore, an increase over ₹1,842 crore year-on-year.
Despite some increase in finance costs and one-time exceptional expenses due to new labour codes, the profit after tax for the quarter, driven by higher operational performances, surged to ₹133.0 crore, an increase of 189% on-year.
The results reflected robust operating performance, supported by increasing contributions from cost-savings initiatives and economies of scale at higher capacity utilization.
Vinati Organics
Vinati Organics is a speciality chemical manufacturer based in Mumbai, India. It was incorporated in 1989 and has grown into a major global player in niche chemical products used by industries like pharmaceuticals, water treatment, personal care, polymers, and oil and gas.
The stock of Vinati Organics has lost almost 20% in the last three years.
Vinati, like some speciality chemicals peers, faced a massive inventory glut. During 2023 and 2024, global customers began destocking—using up existing inventory rather than buying new stock.
Its flagship product, ATBS (used in oil recovery and water treatment), saw a significant volume dip as major clients cut orders. Operating margins have seen a dip in the last four years. In fact, it has fallen from 39.7% in FY21 to 27.9% in FY25.
Like some other peers, things seem to be getting better. In Q3 FY26, Vinati Organics saw revenues improve to ₹530.8 crore vs ₹521.7 crore on-year. However, what was heartening was the improvement in gross profit margins to 29.5% vs 27.3% on-year.
Net profits improved to ₹100.8 crore vs ₹93.7 crore on-year.
Moving ahead, the first phase of the company’s 10,000mtpa expansion of ATBS is now operational and being ramped up. The second phase is expected by May 2026. This will increase their capacity by roughly 25%, allowing Vinati to capture the recovering demand in oil recovery and water treatment.
Clean Science and Technology
Clean Science and Technology is an Indian speciality chemicals company known for its focus on green chemistry and niche, high-margin products.
Founded by technocrats, the company has built its reputation around developing proprietary manufacturing processes that reduce waste, lower emissions, and avoid the use of toxic solvents.
The stock of the company has fallen as much as 46% over the last three years. Clean Science has seen price declines partly because of intensifying competition from Chinese chemical manufacturers, who often offer cheaper alternatives in global markets.
The pricing pressure from increased Chinese capacity has reduced demand and margins. Clean Science has seen operating margins fall systematically from 55.6% in FY21 to 44.1% in FY26.
In Q3 FY26, too, the company witnessed challenges. The management stated it was marked by an uncertain business environment, driven by muted customer offtake, pricing pressure, along with incremental capacities of some of the products, especially in China.
Moving ahead, on the capex side, the hydroquinone and catechol were commercialized in the month of December 2025, and customer trials are ongoing.
With the commercialization of these products, Clean Science will see a moderation in raw material costs of both the end products, that is, TBHQ and Veratrole.
The commercialization of the hydroquinone plant and the expansion of TBHQ are strategically aligned with its purpose-driven growth and value optimization strategy and are expected to enhance existing product margins.
Further capex timeline of Performance Chemical 2 is as per plan, and the company expects to commercialize in Q1 FY27.
Investors should evaluate the company’s fundamentals, corporate governance, and valuations of the stock as key factors when conducting due diligence before making investment decisions.
Happy investing.
Disclaimer: This article is for information purposes only. It is not a stock recommendation and should not be treated as such.
This article is syndicated from Equitymaster.com